USA – Scorpion Therapeutics, Inc., a Boston, MA-based next-generation precision oncology company, closed a $108m Series A financing.
The round was led by Atlas Venture, Omega Funds, and Vida Ventures, with participation from Abingworth and Partners HealthCare Innovation. The company intends to use the funds to advance Precision Oncology 2.0., with the goal of delivering small molecule drugs that are safe and well-tolerated and that can provide durable responses to many more people with cancer. Founded by a team of world-renowned drug developers and researchers in cancer biology and targeted oncology, including Gary D. Glick, Ph.D., Keith Flaherty, M.D., Gaddy Getz, Ph.D., and Liron Bar-Peled, Ph.D., Scorpion provides a drug discovery and development engine which integrates technologies across target discovery, medicinal chemistry, and translational medicine to deliver precision oncology medicines. 29/10/2020
